Moreover, in BRCA1-mutated breast cancers, this sialyltransferase inhibitor was reported to neutralize acidic tumor-permissive microenvironment and sensitize cancer cells to immune checkpoint blockade by activating CD8+ T cells and inhibiting tumor growth and metastasis [50]. Here, CD8A is linked to neoplasm.